Business
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce Biotech webinar \"Alzheimer's Outlook - Neuroinflammation, the Next Step,\" on November 12th, 2024.\nInMed's Senior Vice President of Preclinical Research and Development, Dr. Eric Hsu, will join a panel of experts to speak about recent trends in Alzheimer's disease research and the targeting of neuroinflammation to restrict disease progression. Details are as follows:\nAlzheimer's Outlook - Neuroinflammation, the Next Step\nDate: November 12, 2024\nTime: 2:00pm ET\nRegistration: https://www.fiercebiotech.com/premium/webinar/breakthroughs-alzheimers-research-and-drug-development\nDiscussion topics in this webinar include:\n\nthe latest research into the causes of Alzheimer's disease\nthe different therapeutic pathways being explored\ndrugs in development and their pharmacological targets\nthe pathophysiological effects of neuroinflammation in Alzheimer's disease\n\nSpeakers for this event:\nPhyllis Ferrell, DrPH, MBA (Moderator)Dr. Phyllis Ferrell is the Chief Impact Officer at StartUp Health's Alzheimer's Moonshot. Formerly, she was the Global Head of External Engagement for Alzheimer's disease and neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer's disease development team.\nBarry Greenberg, PhD\nDr. Greenberg is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine, where he is leading the development of an Alzheimer's Disease Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent Alzheimer's at its earliest stages.\nDavid Morgan, PhDDr. Morgan is Director of the Alzheimer's Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. Dr. Morgan's research interests are Alzheimer's disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies.\...